AQP3 and primary effusion lymphoma: Involvement of AQP3 in PEL pathogenesis was studied in context with cyclooxygenase 2 (COX-2) inflammatory pathways, which is a target of nonsteroidal anti-inflammatory drugs (NSAIDs) [45].